Harbinder Singh

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 10

Top Topics

Structure Activity Relationship

Anti Inflammatory

Cardiovascular Risk Factors

Top Venues

Expert opinion on therapeutic patents

Drug development research

Molecular diversity

This page only lists publications with an associated author ORCID identifier.

Publications

Harbinder Singh, Devendra K Agrawal
Recent advancements in the discovery of cereblon-based protease-targeted chimeras with potential for therapeutic intervention. Future medicinal chemistry 14 (19) (2022)
Atamjit Singh, Shilpa Heer, Komalpreet Kaur, Harmandeep K Gulati, Nitish Kumar, Anchal Sharma, Jatinder V Singh, Kavita Bhagat, Gurinder Kaur, Kirandeep Kaur, Harbinder Singh, Renu Chadha, Preet M S Bedi
Design, synthesis, and biological evaluation of isatin-indole-3-carboxaldehyde hybrids as a new class of xanthine oxidase inhibitors. Archiv der Pharmazie 355 (6) (2022)
Jatinder Vir Singh, Shubham Thakur, Nitish Kumar, Harjeet Singh, Venus Singh Mithu, Harpreet Singh, Kavita Bhagat, Harmandeep Kaur Gulati, Anchal Sharma, Harbinder Singh, Sahil Sharma, Preet Mohinder Singh Bedi
Donepezil-Inspired Multitargeting Indanone Derivatives as Effective Anti-Alzheimer's Agents. ACS chemical neuroscience 13 (6) (2022)
Harbinder Singh, Vikrant Rai, Devendra K Agrawal
LPS and oxLDL-induced S100A12 and RAGE expression in carotid arteries of atherosclerotic Yucatan microswine. Molecular biology reports 49 (9) (2022)
Harbinder Singh, Devendra K Agrawal
Therapeutic potential of targeting the receptor for advanced glycation end products (RAGE) by small molecule inhibitors. Drug development research 83 (6) (2022)
Harbinder Singh, Vikrant Rai, Devendra K Agrawal
Discerning the promising binding sites of S100/calgranulins and their therapeutic potential in atherosclerosis. Expert opinion on therapeutic patents 31 (11) (2021)
Harbinder Singh, Vikrant Rai, Sunil K Nooti, Devendra K Agrawal
Novel ligands and modulators of triggering receptor expressed on myeloid cells receptor family: 2015-2020 updates. Expert opinion on therapeutic patents 31 (6) (2021)
Nitish Kumar, Harmandeep Kaur Gulati, Aakriti Sharma, Shilpa Heer, Anupmjot Kaur Jassal, Lovenish Arora, Simranpreet Kaur, Atamjit Singh, Kavita Bhagat, Arshmeet Kaur, Harbinder Singh, Jatinder Vir Singh, Preet Mohinder Singh Bedi
Most recent strategies targeting estrogen receptor alpha for the treatment of breast cancer. Molecular diversity 25 (1) (2020)
Jatinder V Singh, Gurbachan Mal, Gurleen Kaur, Manish K Gupta, Amritpal Singh, Kunal Nepali, Harbinder Singh, Sahil Sharma, Preet Mohinder S Bedi
Benzoflavone derivatives as potent antihyperuricemic agents. MedChemComm 10 (1) (2018)
Jatinder V Singh, Anumeet Kaur, Kavita Bhagat, Manish K Gupta, Manwinder Singh, Harbinder Singh, Preet Mohinder S Bedi
5,6-Benzoflavones as cholesterol esterase inhibitors: synthesis, biological evaluation and docking studies. MedChemComm 9 (3) (2018)